Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma

Trial Profile

Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Eltrapuldencel-T (Primary) ; Melanoma vaccine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Intus
  • Sponsors Caladrius Biosciences; NeoStem Oncology
  • Most Recent Events

    • 25 Apr 2016 Status changed from active, no longer recruiting to discontinued.
    • 12 Jan 2016 Status changed from recruiting to active, no longer recruiting s reported by ClinicalTrials.gov record.
    • 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top